Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. - Satoh,N.; Ogawa,Y.; Usui,T.; Tagami,T.; Kono,S.; Uwaugi,H.; Sugiyama,H.; Sugawara,A.; Yamada,K.; Shimatsu,A.; Kuzuya,H.; Nakao,K. (Diab Care, 2003)